Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

Company has Walker Chandiok & Co. LLP as its auditors. As on 31-12-2024, the company has a total of 8.97 Crore shares outstanding.Home First Finance Co Share Price Today is Rs. 1030.20. On previous ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Merck & Company (MRK – Research Report). The ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

The Senate Finance Committee will meet on Jan. 29 to discuss the confirmation of RFK Jr., whose stances on vaccines and abortion have raised questions from Democrats and Republicans alike.

RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, ...